Rabeprazole
Aciphex, Rabeprazole (rabeprazole) is a small molecule pharmaceutical. Rabeprazole was first approved as Aciphex on 1999-08-19. It is used to treat duodenal ulcer, gastroesophageal reflux, heartburn, helicobacter infections, and zollinger-ellison syndrome in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Aciphex, Rabeprazole (discontinued: Aciphex, Rabeprazole)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Rabeprazole sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ACIPHEX | Waylis Therapeutics | N-020973 RX | 1999-08-19 | 1 products, RLD, RS |
Show 2 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| aciphex | New Drug Application | 2026-01-27 |
| rabeprazole sodium | ANDA | 2026-08-28 |
| rabeprazole sodium delayed-release | NDA authorized generic | 2020-12-29 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A02: Drugs for acid related disorders
— A02B: Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
— A02BC: Proton pump inhibitors for peptic ulcer and gord
— A02BC04: Rabeprazole
— A02BC54: Rabeprazole, combinations
— A02BD: Combinations for eradication of helicobacter pylori
— A02BD12: Rabeprazole, amoxicillin and clarithromycin
— A02BD13: Rabeprazole, amoxicillin and metronidazole
HCPCS
No data
Clinical
Clinical Trials
293 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 58 | 1 | 1 | 2 | — | 62 |
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | 8 | 10 | 20 | 13 | 14 | 62 |
| Infections | D007239 | EFO_0000544 | — | 4 | 4 | 5 | 35 | 16 | 62 |
| Helicobacter infections | D016481 | EFO_1000961 | — | 2 | 3 | 4 | 16 | 13 | 36 |
| Peptic esophagitis | D004942 | EFO_1001095 | — | 2 | 5 | 12 | 7 | 5 | 30 |
| Communicable diseases | D003141 | — | — | 1 | 1 | 3 | 12 | 6 | 22 |
| Ulcer | D014456 | MPATH_579 | — | — | 6 | 7 | 3 | 4 | 15 |
| Duodenal ulcer | D004381 | EFO_0004607 | K26 | — | 5 | 5 | 1 | 3 | 10 |
| Gastritis | D005756 | EFO_0000217 | K29.7 | — | 1 | 1 | 5 | 3 | 9 |
| Heartburn | D006356 | — | R12 | — | — | 4 | 4 | 1 | 9 |
Show 28 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung neoplasms | D008175 | — | C34.90 | — | 3 | 1 | — | — | 3 |
| Small cell lung carcinoma | D055752 | — | — | — | 3 | 1 | — | — | 3 |
| Esophageal diseases | D004935 | EFO_0009544 | K22.9 | — | 1 | 1 | — | — | 2 |
| Non-erosive reflux disease | D000096663 | — | — | — | — | 1 | — | 1 | 2 |
| Asthma | D001249 | EFO_0000270 | J45 | — | — | 1 | — | 1 | 2 |
| Deglutition disorders | D003680 | — | R13.1 | — | 2 | 1 | — | — | 2 |
| Cerebrovascular disorders | D002561 | EFO_0003763 | I60-I69 | — | — | 1 | — | — | 1 |
| Endoscopic mucosal resection | D000069916 | — | — | — | — | 1 | — | — | 1 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | 1 | — | — | 1 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 7 | 5 | — | — | — | 8 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 3 | — | — | — | 3 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | 2 | — | — | — | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 2 | — | — | — | 2 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 1 | 1 | — | — | — | 1 |
| Fallopian tube neoplasms | D005185 | — | — | 1 | 1 | — | — | — | 1 |
| Female genital neoplasms | D005833 | — | — | 1 | 1 | — | — | — | 1 |
| Uterine cervical neoplasms | D002583 | — | — | 1 | 1 | — | — | — | 1 |
| Carcinoma | D002277 | — | C80.0 | 1 | 1 | — | — | — | 1 |
| Urologic neoplasms | D014571 | — | C64-C68 | 1 | 1 | — | — | — | 1 |
Show 6 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug interactions | D004347 | — | — | 4 | — | — | — | — | 4 |
| Pharmacokinetics | D010599 | — | — | 3 | — | — | — | — | 3 |
| Lymphoma | D008223 | — | C85.9 | 2 | — | — | — | 1 | 3 |
| Covid-19 | D000086382 | — | U07.1 | 1 | — | — | — | 1 | 2 |
| Biological availability | D001682 | — | — | 2 | — | — | — | — | 2 |
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | 2 | — | — | — | — | 2 |
| Motor neuron disease | D016472 | EFO_0003782 | G12.2 | 2 | — | — | — | — | 2 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | — | — | — | — | 1 |
| Fatty liver | D005234 | EFO_0003934 | — | 1 | — | — | — | — | 1 |
Show 14 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | — | — | 1 | 1 |
| Community-acquired pneumonia | D000098968 | — | — | — | — | — | — | 1 | 1 |
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | — | — | — | — | 1 | 1 |
| Calcium metabolism disorders | D002128 | EFO_0005769 | E83.5 | — | — | — | — | 1 | 1 |
| Sudden death cardiac | D016757 | EFO_0004278 | — | — | — | — | — | 1 | 1 |
| Death | D003643 | PATO_0001422 | — | — | — | — | — | 1 | 1 |
| Sudden death | D003645 | — | — | — | — | — | — | 1 | 1 |
| Signs and symptoms | D012816 | EFO_0003765 | R68 | — | — | — | — | 1 | 1 |
| Pharyngeal diseases | D010608 | — | — | — | — | — | — | 1 | 1 |
| Patient compliance | D010349 | — | — | — | — | — | — | 1 | 1 |
Show 13 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Rabeprazole |
| INN | rabeprazole |
| Description | Rabeprazole is a member of benzimidazoles, a sulfoxide and a member of pyridines. It has a role as an EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor and an anti-ulcer drug. It is a conjugate acid of a rabeprazole(1-). |
| Classification | Small molecule |
| Drug class | antiulcer agents (benzimidazole derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[nH]2)c1C |
Identifiers
| PDB | — |
| CAS-ID | 117976-89-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1219 |
| ChEBI ID | 8768 |
| PubChem CID | 5029 |
| DrugBank | DB01129 |
| UNII ID | 32828355LL (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Rabeprazole
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,700 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
14,630 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use